Article

High success rate seen with glaucoma device at 1 year

A proprietary miniature glaucoma device (Ex-PRESS, Optonol Ltd.) implanted under a partial-thickness scleral flap achieved significant decreases in IOP in patients with glaucoma.

Key Points

In a retrospective, non-comparative case series of patients, Dr. Netland and colleagues implanted the device under a scleral flap in patients with glaucoma who had elevated IOP that was refractory to maximal medical therapy. The investigators defined successful procedures as those in which the postoperative IOP was between 5 and 21 mm Hg with or without additional medication and without the need for further glaucoma surgery. The valve was implanted in 300 consecutive eyes. The mean follow-up period was 17 months (range, 3 to 36 months).

"The . . . miniature glaucoma device implanted under a scleral flap was safe and effective. Blockage of the lumen of the device in a small proportion of patients was effectively treated," Dr. Netland said.

Previous study

In a previous study, Dr. Netland, Peter Maris Jr., MD, and Kyoko Ishida, MD, compared the outcomes after implantation of the valve with those achieved with standard trabeculectomy.

The average follow-up was 10.8 months (range, 3.5 to 18 months). The investigators reported that, during the early postoperative period, the IOP values in the eyes in which the valve had been implanted were significantly higher than in the eyes that received the standard of care. By the 3-month postoperative evaluation, the degree by which the IOP decreased was similar in both treatment groups, and the number of antiglaucomatous medications did not differ between the groups.

The study showed that the implant shunts aqueous from the anterior chamber into the subconjunctival space adjacent to the limbus.

The investigators reported that "the . . . implant under a scleral flap had similar IOP-lowering efficacy with a lower rate of early hypotony compared with trabeculectomy."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.